Latest From PuriCore PLC
US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.
The US company listed in the UK has been devastated by the failure of its investigational eczema drug in Phase II trials in August and has hired an advisor to look for strategic alternatives, including a sale.
Realm Therapeutics is evaluating a substance derived from insights into innate immunity that has potential as an immunomodulator in various dermatological disorders, including atopic dermatitis and acne, with proof-of-concept (POC) expected in the third quarter.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.
- Infection Control-Sterilization
- Surgical Equipment & Devices
- Therapeutic Areas
- Dental & Oral Products
- Infectious & Viral Diseases
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- PuriCore PLC
- Senior Management
Marella Thorell, Fin. Dir., CFO
Mark Sampson, PhD, VP, Research & Scientific Dev.
Michael Ashton, Exec. Chmn.
- Contact Info
Phone: (0) 1785 782420
Wolseley House, Dyson Way
Beaconside, Stafford , ST18 0GA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.